The clinically approved combinations consist of ICIs (anti-PD-1 plus anti-CTLA4), ICI plus chemotherapy, and ICI plus targeted therapy in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma, breast cancer, urothelial carcinoma, gastric cancer, cervical cancer, and endometrial carcinoma (Table 1). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.